TFX BREAKING NEWS: Teleflex Incorporated 20% Stock Drop Triggers Securities Fraud Investigation; Investors are Urged to Contact BFA Law if they Suffered Losses

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE: TFX) for potential violations of the federal securities laws.

If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.

Why is Teleflex being Investigated?

Teleflex is a global provider of medical technology products used by hospitals and healthcare providers in critical care and surgical applications. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.

Given these announcements, BFA is investigating whether Teleflex and certain of its senior officers made materially false and misleading statements to investors given the company’s past positive representations.

The Stock Declines as the Truth is Revealed

As a result of Teleflex’s announcement on February 27, 2025, the company’s stock price declined approximately 20% during trading.

Click here for more information: https://www.bfalaw.com/cases-investigations/teleflex-incorporated.

What Can You Do?

If you invested in Teleflex you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/teleflex-incorporated

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/the-trade-desk-inc

Attorney advertising. Past results do not guarantee future outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227676608/en/